Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr;1825(2):140-52.
doi: 10.1016/j.bbcan.2011.11.003. Epub 2011 Nov 29.

Progress of molecular targeted therapies for prostate cancers

Weihua Fu  1 , Elena Madan, Marla Yee, Hongtao Zhang
Affiliations
Review

Progress of molecular targeted therapies for prostate cancers

Weihua Fu et al. Biochim Biophys Acta. 2012 Apr.

Abstract

Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in men in the United States. The current standard of care consists of prostatectomy and radiation therapy, which may often be supplemented with hormonal therapies. Recurrence is common, and many develop metastatic prostate cancer for which chemotherapy is only moderately effective. It is clear that novel therapies are needed for the treatment of the malignant forms of prostate cancer that recur after initial therapies, such as hormone refractory (HRPC) or castration resistant prostate cancer (CRPC). With advances in understanding of the molecular mechanisms of cancer, we have witnessed unprecedented progress in developing new forms of targeted therapy. Several targeted therapeutic agents have been developed and clinically used for the treatment of solid tumors such as breast cancer, non-small cell lung cancer, and renal cancer. Some of these reagents modulate growth factors and/or their receptors, which are abundant in cancer cells. Other reagents target the downstream signal transduction, survival pathways, and angiogenesis pathways that are abnormally activated in transformed cells or metastatic tumors. We will review current developments in this field, focusing specifically on treatments that can be applied to prostate cancers. Finally we will describe aspects of the future direction of the field with respect to discovering biomarkers to aid in identifying responsive prostate cancer patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Prostate cancer's progression and treatment
Prostate cancer patients with high risk are recommended to have surgery, radiation, and/or hormone therapies. Although these treatments are efficient in general, some patients have recurrent diseases, at which stage current treatment options, mostly chemotherapy, are limited in terms of clinical outcome. It is hoped that development in targeted therapies can provide more options for the recurrent and metastatic prostate cancers.
Figure 2
Figure 2. Molecular targets and designed intervention in targeted therapies for prostate cancer
In addition to androgen/ androgen receptor (AR) pathways, many growth receptors (EGFR/HER2, IGFR, PDGFR, and VEGFR), and their downstream molecules, have been explored as the targets to block growth signaling of tumor cells or the angiogenesis process that provides nutrients to cancer cells. Antibodies to some prostate cancer specific antigens (e.g. PSMA and the F77 antigen) have also been developed.
Figure 3
Figure 3
Structure of small molecule agents in targeted therapies for prostate cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523. - PubMed
    1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama. 2005;294:433–439. - PubMed
    1. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226–5234. - PMC - PubMed
    1. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Jr., Lilja H, Scardino PT. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973–3978. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154. - PubMed

Publication types

MeSH terms

Substances